Table 2.
Correlation of MSI with hMLH1 and hMSH2 Expression
| Case | MSI status* | BAT-26 Status† | IHC‡ |
|---|---|---|---|
| G15 | MSI-H | I | hMLH1 loss |
| G65 | MSI-H | I | hMLH1 loss |
| G134 | MSI-H | I | hMLH1 loss |
| G135 | MSI-H | I | hMLH1 loss |
| G165 | MSI-H | I | hMLH1 loss |
| G38 | MSI-H | I | hMSH2 loss |
| G61 | MSI-H | I | hMSH2 loss |
| G106 | MSI-H | I | hMSH2 loss |
| G30 | MSI-L | S | No loss |
| G56 | MSI-L | S | No loss |
| G59 | MSI-L | S | No loss |
| G99 | MSI-L | S | No loss |
| G119 | MSI-L | S | No loss |
*MSI status was categorized as MSI-H for cases demonstrating >33% of loci instable and MSI-L for cases demonstrating <17% of loci instable.
†I, Instability observed in the tumor DNA; S, no instability observed at this mononucleotide repeat marker.
‡Immunohistochemical staining results: No loss, positive nuclear staining of neoplastic cells for hMHL1 and hMSH2 observed; loss, absence of nuclear neoplastic cell staining for hMLH1 or hMSH2.